
    
      This is a double-blind, randomized, parallel-group, controlled, repeat dose, single center
      study to evaluate the safety and efficacy of repeat application of RT001 in at least 30
      subjects with moderate to severe lateral canthal lines. Subjects will be randomized to 1 of 2
      treatment groups in a 1:1 ratio (RT001 Dose A or vehicle control).
    
  